Independent Research
ARWR Analysis
4 pieces of research on Arrowhead Pharmaceuticals, Inc.. We find the signal management buried in the earnings call.
Arrowhead's 750-Patient Heart Data: A $12B Test
Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, with no appro…
Read analysis →Arrowhead Directors Sell $1.19M Ahead of Key Heart Data
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18, days before a 750-patient cardiovascular dataset is due at a late-…
Read analysis →Arrowhead Directors Sell $1.2M as REDEMPLO Nears EU Vote
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in stock on August 18 while shares were gaining 7% on European REDEMPLO regulatory progres…
Read analysis →ARWR Jumps on Phase 3 Trial Win, Analysts Raise Targets
Arrowhead Pharmaceuticals surged after positive Phase 3 results that analysts called a "best-case scenario," with Piper Sandler and Chardan raising targets to $…
Read analysis →